{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:30:06Z","timestamp":1775626206551,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-68462-9","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T09:34:04Z","timestamp":1769420044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intranasal administration of broad-spectrum macrocyclic peptide inhibitor protects against SARS-CoV-2 Omicron variants"],"prefix":"10.1038","volume":"17","author":[{"given":"Min","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7996-1119","authenticated-orcid":false,"given":"Shuofeng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoli","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7737-8912","authenticated-orcid":false,"given":"Vincent Kwok-Man","family":"Poon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7089-4829","authenticated-orcid":false,"given":"Chris Chung-Sing","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5087-3614","authenticated-orcid":false,"given":"Anna Jinxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6466-5958","authenticated-orcid":false,"given":"Junhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaning","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7508-4953","authenticated-orcid":false,"given":"Alex A.","family":"Compton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1702-6335","authenticated-orcid":false,"given":"Youming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6489-4459","authenticated-orcid":false,"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3869-615X","authenticated-orcid":false,"given":"George Fu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9389-4928","authenticated-orcid":false,"given":"Hongwei","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6336-6657","authenticated-orcid":false,"given":"Jasper Fuk-Woo","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2466-2167","authenticated-orcid":false,"given":"Yizhen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3053-2687","authenticated-orcid":false,"given":"Yi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"68462_CR1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa2311330","volume":"390","author":"A Hampshire","year":"2024","unstructured":"Hampshire, A. et al. Cognition and memory after COVID-19 in a large community sample. N. Engl. J. Med. 390, 806\u2013818 (2024).","journal-title":"N. Engl. J. Med."},{"key":"68462_CR2","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","volume":"183","author":"Y Xie","year":"2023","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern. Med. 183, 554\u2013564 (2023).","journal-title":"JAMA Intern. Med."},{"key":"68462_CR3","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1001\/jamainternmed.2023.5099","volume":"183","author":"KW Fung","year":"2023","unstructured":"Fung, K. W., Baye, F., Baik, S. H. & McDonald, C. J. Nirmatrelvir and molnupiravir and post-COVID-19 condition in older patients. JAMA Intern. Med. 183, 1404\u20131406 (2023).","journal-title":"JAMA Intern. Med."},{"key":"68462_CR4","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"LH Liu","year":"2022","unstructured":"Liu, L. H. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676\u2013681 (2022).","journal-title":"Nature"},{"key":"68462_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","volume":"604","author":"S Iketani","year":"2022","unstructured":"Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553\u2013556 (2022).","journal-title":"Nature"},{"key":"68462_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41579-024-01036-y","volume":"22","author":"JF-W Chan","year":"2024","unstructured":"Chan, J. F.-W., Yuan, S., Chu, H., Sridhar, S. & Yuen, K.-Y. COVID-19 drug discovery and treatment options. Nat. Rev. Microbiol. 22, 391\u2013407 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"68462_CR7","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","volume":"622","author":"Y Duan","year":"2023","unstructured":"Duan, Y. et al. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nature 622, 376\u2013382 (2023).","journal-title":"Nature"},{"key":"68462_CR8","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1056\/NEJMoa2309003","volume":"390","author":"J Hammond","year":"2024","unstructured":"Hammond, J. et al. Nirmatrelvir for vaccinated or unvaccinated adult outpatients with Covid-19. N. Engl. J. Med. 390, 1186\u20131195 (2024).","journal-title":"N. Engl. J. Med."},{"key":"68462_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","volume":"20","author":"M Muttenthaler","year":"2021","unstructured":"Muttenthaler, M., King, G. E., Adams, D. J. & Alewood, P. E. Trends in peptide drug discovery. Nat. Rev. Drug Discov. 20, 309\u2013325 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"68462_CR10","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1021\/jacs.8b13178","volume":"141","author":"AA Vinogradov","year":"2019","unstructured":"Vinogradov, A. A., Yin, Y. Z. & Suga, H. Macrocyclic peptides as drug candidates: recent progress and remaining challenges. J. Am. Chem. Soc. 141, 4167\u20134181 (2019).","journal-title":"J. Am. Chem. Soc."},{"key":"68462_CR11","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.aap7577","volume":"358","author":"P Hosseinzadeh","year":"2017","unstructured":"Hosseinzadeh, P. et al. Comprehensive computational design of ordered peptide macrocycles. Science 358, 1461\u20131466 (2017).","journal-title":"Science"},{"key":"68462_CR12","first-page":"655","volume":"3","author":"H Murakami","year":"2006","unstructured":"Murakami, H., Ohta, A., Ashigai, H. & Suga, H. A highly flexible tRNA acylation method for non-natural polypeptide synthesis. Nat. Methods 3, 655\u2013655 (2006).","journal-title":"Nat. Methods"},{"key":"68462_CR13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/nprot.2011.331","volume":"6","author":"Y Goto","year":"2011","unstructured":"Goto, Y., Katoh, T. & Suga, H. Flexizymes for genetic code reprogramming. Nat. Protoc. 6, 779\u2013790 (2011).","journal-title":"Nat. Protoc."},{"key":"68462_CR14","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.chembiol.2011.09.013","volume":"18","author":"Y Yamagishi","year":"2011","unstructured":"Yamagishi, Y. et al. Natural product-like macrocyclic N-methyl-peptide inhibitors against a ubiquitin ligase uncovered from a ribosome-expressed de novo library. Chem. Biol. 18, 1562\u20131570 (2011).","journal-title":"Chem. Biol."},{"key":"68462_CR15","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1021\/acs.accounts.1c00391","volume":"54","author":"Y Goto","year":"2021","unstructured":"Goto, Y. & Suga, H. The RaPID platform for the discovery of pseudo-natural macrocyclic peptides. Acc. Chem. Res. 54, 3604\u20133617 (2021).","journal-title":"Acc. Chem. Res"},{"key":"68462_CR16","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1021\/acscentsci.0c01708","volume":"7","author":"A Norman","year":"2021","unstructured":"Norman, A. et al. Discovery of cyclic peptide ligands to the SARS-CoV-2 spike protein using mRNA display. ACS Cent. Sci. 7, 1001\u20131008 (2021).","journal-title":"ACS Cent. Sci."},{"key":"68462_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45075-8","volume":"15","author":"GL Shi","year":"2024","unstructured":"Shi, G. L. et al. Omicron Spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue. Nat. Commun.\u00a015, 889 (2024).","journal-title":"Nat. Commun"},{"key":"68462_CR18","doi-asserted-by":"crossref","unstructured":"Zhang, A. J. et al. Coinfection by severe acute respiratory syndrome coronavirus 2 and influenza A(H1N1)pdm09 virus enhances the severity of pneumonia in golden Syrian hamsters. Clin. Infect. Dis. 72, 978\u2013992 (2021).","DOI":"10.1093\/cid\/ciaa1747"},{"key":"68462_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","volume":"23","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 23, 189\u2013199 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"68462_CR20","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.7150\/thno.74428","volume":"12","author":"AP Silwal","year":"2022","unstructured":"Silwal, A. P. et al. DNA aptamers inhibit SARS-CoV-2 spike-protein binding to hACE2 by an RBD- independent or dependent approach. Theranostics 12, 5522\u20135536 (2022).","journal-title":"Theranostics"},{"key":"68462_CR21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1126\/science.abd9909","volume":"370","author":"LX Cao","year":"2020","unstructured":"Cao, L. X. et al. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science 370, 426-431 (2020).","journal-title":"Science"},{"key":"68462_CR22","doi-asserted-by":"publisher","first-page":"e0240004","DOI":"10.1371\/journal.pone.0240004","volume":"15","author":"G Jaiswal","year":"2020","unstructured":"Jaiswal, G. & Kumar, V. In-silico design of a potential inhibitor of SARS-CoV-2 S protein. PLoS ONE 15, e0240004 (2020).","journal-title":"PLoS ONE"},{"key":"68462_CR23","doi-asserted-by":"publisher","first-page":"e02451","DOI":"10.1128\/mBio.02451-20","volume":"11","author":"F Curreli","year":"2020","unstructured":"Curreli, F. et al. Stapled peptides based on human angiotensin-converting enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection. mBio 11, e02451\u201302420 (2020).","journal-title":"mBio"},{"key":"68462_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1021\/acs.bioconjchem.0c00664","volume":"32","author":"RC Larue","year":"2021","unstructured":"Larue, R. C. et al. Rationally designed ACE2-derived peptides inhibit SARS-CoV-2. Bioconjugate Chem. 32, 215\u2013223 (2021).","journal-title":"Bioconjugate Chem."},{"key":"68462_CR25","doi-asserted-by":"publisher","first-page":"14955","DOI":"10.1021\/acs.jmedchem.1c00655","volume":"64","author":"PA Valiente","year":"2021","unstructured":"Valiente, P. A. et al. Computational design of potent D-peptide inhibitors of SARS-CoV-2. J. Med. Chem. 64, 14955\u201314967 (2021).","journal-title":"J. Med. Chem."},{"key":"68462_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab243","volume":"22","author":"PF Pei","year":"2021","unstructured":"Pei, P. F. et al. Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein. Brief. Bioinform. 22, bbab243 (2021).","journal-title":"Brief. Bioinform."},{"key":"68462_CR27","doi-asserted-by":"crossref","unstructured":"Yang, J. et al. Selection and engineering of broad-spectrum antiviral affibody peptide against SARS-CoV-2 variants. hLife. 9, 448\u2013451 (2025).","DOI":"10.1016\/j.hlife.2025.04.010"},{"key":"68462_CR28","doi-asserted-by":"crossref","unstructured":"Thijssen, V. et al. A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein. Proc. Natl. Acad. Sci. USA 120, e2303292120 (2023).","DOI":"10.1073\/pnas.2303292120"},{"key":"68462_CR29","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s11427-023-2410-5","volume":"66","author":"LL Wu","year":"2023","unstructured":"Wu, L. L. et al. A pan-coronavirus peptide inhibitor prevents SARS-CoV-2 infection in mice by intranasal delivery. Sci. China Life Sci. 66, 2201\u20132213 (2023).","journal-title":"Sci. China Life Sci."},{"key":"68462_CR30","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/infdis\/jiy152","volume":"218","author":"C Mathieu","year":"2018","unstructured":"Mathieu, C., Porotto, M., Figueira, T. N., Horvat, B. & Moscona, A. Fusion inhibitory lipopeptides engineered for prophylaxis of Nipah virus in primates. J. Infect. Dis. 218, 218\u2013227 (2018).","journal-title":"J. Infect. Dis."},{"key":"68462_CR31","volume":"5","author":"Y Shi","year":"2024","unstructured":"Shi, Y. Drug development in the AI era: AlphaFold 3 is coming!\u00a0Innovation 5, 100685 (2024).","journal-title":"Innovation"},{"key":"68462_CR32","doi-asserted-by":"crossref","unstructured":"Chan, J. F. W. et al. Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2. Cell Rep. Med. 3,100743 (2022).","DOI":"10.1016\/j.xcrm.2022.100743"},{"key":"68462_CR33","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1038\/s41596-020-0394-5","volume":"15","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat. Protoc. 15, 3699\u20133715 (2020).","journal-title":"Nat. Protoc."},{"key":"68462_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.hlife.2023.10.002","volume":"2","author":"L Wu","year":"2024","unstructured":"Wu, L. et al. Efficient inhibition of SARS-CoV-2 emerging EG.5, EG.5.1 and BA.2.86 variants by fusion inhibitor HY3000 peptide. hLife 2, 43\u201346 (2024).","journal-title":"hLife"},{"key":"68462_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.hlife.2024.12.006","volume":"3","author":"C Su","year":"2025","unstructured":"Su, C. et al. Enabling the immune escaped etesevimab fully-armed against SARS-CoV-2 Omicron subvariants including KP.2. hLife 3, 132\u2013145 (2025).","journal-title":"hLife"},{"key":"68462_CR36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI160766","volume":"132","author":"GL Shi","year":"2022","unstructured":"Shi, G. L. et al. Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2. J. Clin. Investig. 132, e160766 (2022).","journal-title":"J. Clin. Investig."},{"key":"68462_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103643","volume":"73","author":"H Shuai","year":"2021","unstructured":"Shuai, H. et al. Emerging SARS-CoV-2 variants expand species tropism to murines. EBioMedicine 73, 103643 (2021).","journal-title":"EBioMedicine"},{"key":"68462_CR38","doi-asserted-by":"crossref","unstructured":"Shuai, H. et al. Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-\u03b2 and IFN inducer. J. Infect. 81, e1\u2013e10 (2020).","DOI":"10.1016\/j.jinf.2020.07.016"},{"key":"68462_CR39","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nmeth.4193","volume":"14","author":"SQ Zheng","year":"2017","unstructured":"Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331\u2013332 (2017).","journal-title":"Nat. Methods"},{"key":"68462_CR40","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jsb.2015.08.008","volume":"192","author":"A Rohou","year":"2015","unstructured":"Rohou, A. & Grigorieff, N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 192, 216\u2013221 (2015).","journal-title":"J. Struct. Biol."},{"key":"68462_CR41","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A. et al. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"68462_CR42","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"68462_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12\u201321 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"68462_CR44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/pro.3235","volume":"27","author":"TD Goddard","year":"2018","unstructured":"Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27, 14\u201325 (2018).","journal-title":"Protein Sci."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68462-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68462-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68462-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T16:18:32Z","timestamp":1771345112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68462-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68462"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-68462-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Two patents describing potential treatments for COVID using 6L3-related peptides were applied, and the authors listed on the application are Y.S., G.F.G., M.W., J.Y., and Q.P. One patent describing potential treatments for COVID using 6L3-3P11hR and 6L3-1F3P11hR peptides was in application, and the authors listed on the application are Y.S., M.W., J.Y., Q.P., H.H., and Y.F.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1753"}}